E-LIB Suche - Ergebnisse für: Cussac, A. Llombart

1

198P Pembrolizumab plus olaparib vs pembrolizumab plus chem..:

Cussac, A. Llombart ; Rugo, H.S. ; Robson, M.E....
ESMO Open. 9 (2024) - p. 103220 , 2024

Link: https://doi.org/10.1016/..

2

74P Assessing the implementation of the HER2DX genomic test..:

Cejalvo, J.M. ; Soberino, J. ; Ciruelos, E.M....
ESMO Open. 9 (2024) - p. 103080 , 2024

Link: https://doi.org/10.1016/..

3

1MO HER2DX assay and survival outcomes: An individual-patie..:

Javierre, G. Villacampa ; Cortés, J. ; García, J.M. Pérez...
ESMO Open. 9 (2024) - p. 103011 , 2024

Link: https://doi.org/10.1016/..

4

260P LUZERN: Phase II trial of niraparib and aromatase inhi..:

Blanch, S. ; Balmaña, J. ; Roso, L. Lema...
ESMO Open. 9 (2024) - p. 103281 , 2024

Link: https://doi.org/10.1016/..

5

258TiP A phase II trial of loperamide (L) and granulocyte c..:

Pérez-García, J.M. ; Cortes, M. Gion ; Bueno, A. Martinez...
ESMO Open. 8 (2023) 1 - p. 101446 , 2023

Link: https://doi.org/10.1016/..

6

5P HER2DX risk-score in HER2-positive (HER2+) breast cancer..:

Saez, O. Martinez ; Brasó-Maristany, F. ; Griguolo, G....
ESMO Open. 8 (2023) 1 - p. 101229 , 2023

Link: https://doi.org/10.1016/..

7

168P Usefulness of liquid biopsy in the management of patie..:

Barreira, J.J. Iranzo ; Martinez, J. Vidal ; Criado, R. Gisbert...
ESMO Open. 8 (2023) 1 - p. 102017 , 2023

Link: https://doi.org/10.1016/..

8

134P Impact of pre-operative MammaPrint/BluePrint use for f..:

Marin-Liebana, S. ; Morales, S. ; Torres, A. Anton...
ESMO Open. 8 (2023) 1 - p. 101473 , 2023

Link: https://doi.org/10.1016/..

9

7P Independent validation of HER2DX ERBB2 mRNA score to pre..:

Torres, E. Sanfeliu ; Villacampa, G. ; Pascual, T....
ESMO Open. 8 (2023) 1 - p. 101231 , 2023

Link: https://doi.org/10.1016/..

10

SEOM clinical guidelines for the management of metastatic b..:

Llombart Cussac, A. ; de la Haba Rodríguez, J. ; Ruiz Simón, A...
Clinical and Translational Oncology. 15 (2013) 12 - p. 1004-1010 , 2013

Link: https://doi.org/10.1007/..

11

2044 POSTER Phase II trial with letrozole (2.5 mg) to maxim..:

Llombart Cussac, A. ; Galán, A. ; Fuster, C....
European Journal of Cancer Supplements. 5 (2007) 4 - p. 197 , 2007

Link: https://doi.org/10.1016/..

12

PP-5-2 Neo-Adjuvant High-Dose FEC Regimen (H-FEC) with G-CS..:

Llombart Cussac, A. ; Dohollou, N. ; Rhor, A....
European Journal of Cancer. 32 (1996) - p. 34 , 1996

Link: https://doi.org/10.1016/..

13

The role of 18F-FDG PET/CT in the management of Merkel cell..:

López Prior, V. ; Llombart Cussac, B.
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 40 (2021) 3 - p. 139-148 , 2021

Link: https://doi.org/10.1016/..

14

Carcinoma de células de Merkel: diagnóstico y tratamiento e..:

Vázquez Doval, J. ; Llombart Cussac, B. ; Pérez Bustillo, A....
Actas Dermo-Sifiliográficas. 110 (2019) 6 - p. 460-468 , 2019

Link: https://doi.org/10.1016/..

15

Carcinoma adenoide quístico:

Alfaro-Rubio, A. ; Sanmartín Jiménez, O. ; Serra-Guillén, C....
Actas Dermo-Sifiliográficas. 97 (2006) 9 - p. 578-580 , 2006

Link: https://doi.org/10.1016/..